Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study-Reference-Cited by-同舟云学术

Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study

Published:2013-11-28 Issue:2 Volume:26 Page:76-80
ISSN:0955-9930
Container-title:International Journal of Impotence Research
language:en
Short-container-title:Int J Impot Res

Author:

Shim Y S,Pae C-U,Cho K J,Kim S W,Kim J C,Koh J S

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://www.nature.com/articles/ijir201338.pdf

Reference32 articles.

1. Stehlik J, Movsesian MA . Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure. J Card Fail 2009; 15: 31–34.

2. Giannitsas K, Mitropoulos D, Konstantinopoulos A, Athanasopoulos A, Perimenis P . Phosphodiesterase-5 inhibitors in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia. Expert Opin Pharmacother 2008; 9: 1687–1693.

3. Bednar MM . The role of sildenafil in the treatment of stroke. Curr Opin Investig Drugs 2008; 9: 754–759.

4. Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M et al. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 2002; 33: 2675–2680.

5. Rodefer JS, Saland SK, Eckrich SJ . Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats. Neuropharmacology 2012; 62: 1182–1190.

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biopsychosocial determinants of sexual health in older age: the role of health-related, relationship, and psychosexual factors;The Journal of Sexual Medicine;2024-03-15

2. Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism;The Aging Male;2023-12-26

3. Phosphodiesterase inhibitors in psychiatric disorders;Psychopharmacology;2023-04-15

4. Phosphodiesterase inhibitor and selective serotonin reuptake inhibitor combination therapy versus monotherapy for the treatment of major depressive disorder: a systematic review and meta-analysis;International Clinical Psychopharmacology;2023-02-08

5. Pathophysiology and Management Approaches in Alzheimer’s Disease;Drug Delivery Strategies in Neurological Disorders: Challenges and Opportunities;2023